IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Malagola, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.591
EU - Europa 6.422
AS - Asia 3.290
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 13
SA - Sud America 12
Totale 23.369
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.544
UA - Ucraina 2.315
CN - Cina 2.235
DE - Germania 954
PL - Polonia 790
HK - Hong Kong 715
IT - Italia 686
FI - Finlandia 503
IE - Irlanda 384
GB - Regno Unito 276
SE - Svezia 257
IN - India 152
FR - Francia 146
SG - Singapore 67
TR - Turchia 66
CA - Canada 41
BE - Belgio 40
RU - Federazione Russa 24
VN - Vietnam 23
EU - Europa 20
MU - Mauritius 14
AU - Australia 13
DK - Danimarca 13
NL - Olanda 12
JP - Giappone 7
IR - Iran 6
BR - Brasile 5
GR - Grecia 4
BO - Bolivia 3
CO - Colombia 3
CU - Cuba 3
EG - Egitto 3
HU - Ungheria 3
RO - Romania 3
TH - Thailandia 3
ZA - Sudafrica 3
AZ - Azerbaigian 2
ES - Italia 2
HR - Croazia 2
IL - Israele 2
KR - Corea 2
LV - Lettonia 2
MX - Messico 2
MY - Malesia 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
EE - Estonia 1
ID - Indonesia 1
IQ - Iraq 1
JO - Giordania 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MS - Montserrat 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
Totale 23.369
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.001
Jacksonville 1.613
Fairfield 1.565
Houston 1.310
Ann Arbor 1.125
Ashburn 800
Warsaw 790
Princeton 736
Cambridge 732
Wilmington 728
Hong Kong 714
Chandler 629
Seattle 608
Nanjing 536
Dublin 380
Beijing 295
New York 288
Nanchang 227
Helsinki 222
Des Moines 159
Brescia 151
Changsha 125
Jinan 120
Shenyang 119
Hebei 118
Dearborn 110
San Diego 107
Tianjin 102
Jiaxing 84
Milan 78
Shanghai 77
Hangzhou 69
Kunming 66
Kocaeli 64
Ningbo 54
Regensburg 50
Verona 46
Brussels 40
Pune 40
Zhengzhou 38
London 36
Lanzhou 32
Guangzhou 30
Taizhou 29
Haikou 26
Norwalk 26
Orange 26
San Francisco 26
Grafing 25
Toronto 23
Dong Ket 22
Rome 16
Bologna 14
Taiyuan 13
Barlassina 12
Genoa 12
Hefei 12
Helsingør 12
Kilburn 12
North York 12
Westminster 11
Darfo 10
Fuzhou 10
Augusta 9
Hounslow 9
Boardman 8
Changchun 8
Chiswick 7
Melbourne 7
Phoenix 7
Redwood City 7
Nürnberg 6
Turin 6
Chicago 5
Crema 5
Falkenstein 5
Leawood 5
New Bedfont 5
Singapore 5
São Paulo 5
Tokyo 5
Wandsworth 5
Ardabil 4
Battipaglia 4
Bergamo 4
Canberra 4
Como 4
Hanover 4
Lappeenranta 4
Los Angeles 4
Pescara 4
Porto 4
Prescot 4
Alzano Lombardo 3
Athens 3
Brendola 3
Brooklyn 3
Chiari 3
La Habana 3
Lancaster 3
Totale 17.747
Salva come PNG Salva come JPEG
Nome #
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 258
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis 254
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients 237
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 225
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation 216
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 192
Zebrafish disease models in hematology: Highlights on biological and translational impact 169
Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 134
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria 131
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 126
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 125
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 121
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. 118
EXPRESSION OF TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ONGOING RESULTS OF A PROSPECTIVE STUDY. 117
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 116
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 116
A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation 116
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 113
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 112
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 112
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 109
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. 107
Central nervous system angiitis in Hodgkin's disease. 104
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 103
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 102
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 102
Central Venous Catheter-Related Bloodstream Infection Caused by Brevibacterium casei in a Hematology Patient 101
PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE 100
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 100
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 99
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 99
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia 98
Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. 98
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. 98
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-kit positive acute myeloid leukemia. Results of an italian multicentric phase II study. 97
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 97
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 96
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 95
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 94
Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway. 93
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT. 93
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 93
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing 93
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 93
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 93
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 92
Expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation: ongoing results of a prospective study. 92
Conditioning regimens in acute myeloid leukemia. 92
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 92
Acute graft-versus-host disease and expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation 91
Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently with Graft-Versus-Host Disease and Relapse 90
WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia. 90
Changes in Circulating Endothelial Cells Count Could Become a Valuable Tool in the Diagnostic Definition of Acute Graft-Versus-Host Disease. 89
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 89
The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era 89
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 88
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. 88
Low dose AraC for Myelodysplastic Syndromes: is it still a current therapy ?. 88
Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression 88
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 87
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 87
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 87
Development of a cell culture model based on biocompatible polymeric scaffolds engineered with human Mesenchymal Stromal Cells (MSCs) for cartilage and bone regenerative therapy 87
Liposomal daunorubicin (DAUNOXOME) for treatment of relapsed meningeal acute myeloid leukemia. 86
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 86
Treatment of Chronic Myeloid Leukemia elderly patients in the Tyrosine Kinase Inhibitor era. 86
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 85
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. 85
FLAIE (fludarabine, cytarabine, idarubicin and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: a single center experience. 85
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 84
Four Drugs combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as induction therapy for newly diagnosed acute myeloid leukemia patients younger than 65 yrs: response and follow up of 127 patients. 84
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 83
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 83
Brentuximab vedotin in patients with hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four italian centers 83
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 82
Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor 82
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 81
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients 81
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 81
D1CLEARANCE OF HEPATITIS B VIRUS INFECTION IN A PATIENT RECEIVING ALLOGENEIC BONE MARROW TRANSPLANTATION FROM AN HBV NAIVE DONOR. 81
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 80
Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. 79
Assoication of 3q21 syndrome with different RPN1/EVI1 fusion transcript in AML patients. 79
Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML 79
Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome 79
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 79
AIDA: The italian way of treating acute promyelocytic leukemia (APL): final act . 79
Liposomal daunorubicin (DaunoXome) for the treatment of relapsed meningeal acute myeloid leukemia. 78
Chemotherapy of secondary leukemias 77
Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. 77
5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic (MDS) patients. clinical and biological effects. 77
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 77
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 77
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. 77
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 76
Establishing a New Zebrafish Model to Study Malignant Transformation in Myeloproliferative Disorders. 76
Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 76
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 76
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 75
Imatinib Mesylate can induce complete molecular remission in FIP1L1-PDGFR-alpha positive idiopatic hypereosinophilic sindrome. 75
Totale 10.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.908
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.908
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019820 0 0 0 0 0 0 0 0 0 166 299 355
2019/20205.900 861 105 124 605 270 655 606 651 450 898 209 466
2020/20214.695 61 482 83 671 139 626 191 625 621 557 459 180
2021/20222.684 121 460 55 130 111 203 128 194 141 365 203 573
2022/20232.153 435 45 53 175 162 597 7 199 259 30 91 100
2023/20242.103 125 72 190 140 130 457 122 93 758 16 0 0
Totale 24.326